You are here: Industry Insights > Pharma in China

News List

Amidst contentious debates, what path will the FDA take with accelerated approvals? Krebs Qin
May 06, 2024
Accelerated approval is a privilege that every applicant desires.
Drug Apocalypse of the Future: Artificial Intelligence Discovers New Antibiotics, Disrupting Traditional Innovations Big Cat of Medical Field
March 11, 2024
At present, the use of artificial intelligence to participate in the discovery and design of new drugs has become a hot track for new drug research and development.
Joining Forces with Zai Lab: What is the Remaining Market Potential for Opdivo in China? Yefenghong
March 06, 2024
Bristol Myers Squibb (BMS) recently announced the transfer of sales rights for one of its core products, the PD-1 monoclonal antibody Opdivo (nivolumab), in select provinces within China to the local biotechnology firm Zai Lab Limited (ZLAB).
Becoming Contracted Authors of PharmaSources PharmaSources.com
February 26, 2024
Join PharmaSources.com to share your insights into the pharmaceutical industry with hundreds of industrial KOLs in a league!
Looking at the ADC Territory of Two Industry Pioneers From the DS-8201 Patent Dispute Yefenghong
January 02, 2024
A study by renowned American economist Edwin Mansfield suggests that 60% of new drugs would not be invented without patent protection, highlighting the importance of patent protection in the pharmaceutical industry today.
Global Pharmaceutical Companies' Dream of Nuclear Medicine Yefenghong
January 02, 2024
Recently, Novartis announced that it will invest in establishing a new radiopharmaceutical production site in China, in order to accelerate the introduction of innovative radioligand therapy to China.
Domestic New Drug R&D Strength is Gradually Ascending, and Overseas Product Authorization is in Full Swing WND/PharmaSources
December 14, 2023
On November 13th, LEGN.US reached an 1 billion US dollar cooperation agreement with Novartis Pharmaceuticals.
Next Stop for PD-1? MNC for Subcutaneous Preparation Takes the Lead in Competition, Leading to A More Fierce Domestic Conpetition, but Differentiation is not easy Spur 203/PharmaSources
December 14, 2023
The competition for the subcutaneous formulation of PD-1/PD-L1 inhibitors has been spreading globally for a long time, with Roche and Bristol Myers Squibb currently leading the pack.
Initial CRISPR Gene Editing Therapy has been Approved. What is the Domestic Progress? Yefenghong/PharmaSources
December 14, 2023
Vertex Pharmaceuticals and CRISPR Therapeutics announced that their jointly developed CRISPR gene editing therapy CASGEVY has been conditionally approved.
Great Market Potential: Important Nodes in the Domestic RSV Pharmaceutical Field Xiaoyaowan
December 14, 2023
Respiratory syncytial virus (RSV) is a common enveloped RNA virus that circulates in the winter and spring. It is mainly transmitted by direct contact with the nasal secretions and respiratory droplets of infected individuals.